Bristol-Myers Squibb Company (NYSE:BMY) Shooting Higher to New Recent High

Bristol-Myers Squibb Company (NYSE:BMY) Shooting Higher to New Recent High

During the past six months, Bristol-Myers Squibb Company (NYSE:BMY)'s stock has been 23.70% and 30.67% for the last 12 months. The institutional investor held 165,729 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $9.24 million, up from 18,315 at the end of the previous reported quarter. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 56.73%. It closed at $65.35 lastly. The ex-dividend date will be Thursday the 5th of October 2017. It has underperformed by 39.89% the S&P500.

Clifford Swan Investment Counsel Llc increased Bristol (BMY) stake by 6.92% reported in 2017Q2 SEC filing. From the opening price, the stock has seen a change of 0.14% recently clocking in with a price of $65.60. The business's revenue was up 5.6% compared to the same quarter a year ago. Verizon Communications Inc now has $195.84 billion valuation. (NYSE:WD) has risen 103.91% since October 12, 2016 and is uptrending. It has outperformed by 9.18% the S&P500. The NYSE listed company saw a recent bid of 3.30 on 1618 volume. Alaska Air Group Inc (NYSE:ALK) was raised too.

Investors sentiment increased to 2.39 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It improved, as 4 investors sold Model N Inc shares while 14 reduced holdings. Manning Napier Ltd Liability Corp reported 2.03 million shares.

First Manhattan Co. trimmed its position in Bristol-Myers Squibb Company (NYSE:BMY) by 1.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. First United Bancorporation Tru holds 38,598 shares or 1.46% of its portfolio. Lucas Management reported 2.81% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Chatham Capital Group Inc Inc invested in 7,445 shares. Looking out over the past year, company shares have been recorded -0.20% off the 52 week high and 42.58% away from the low over the same period. Sol Capital Mngmt Co has invested 0.37% in Bristol-Myers Squibb Co (NYSE:BMY). Cullinan Associate reported 132,246 shares.

Kura Oncology, Inc. (KURA) stock moved with shift of 0.36% in the past week. 654,264 are held by Huntington Commercial Bank.

Bristol-Myers Squibb Company (BMY) pulled off a 0.37 percent gain and now trades for $65.35. Therefore 0 are positive. Overall, Bristol-Myers Squibb is up almost 25% during the past six months, and is on pace for its fifth straight monthly win. Deutsche Bank maintained the shares of BMY in report on Monday, July 17 with "Hold" rating. The company has market cap of $1.24 billion. The firm has "Sell" rating given on Monday, June 5 by BMO Capital Markets. The company was maintained on Thursday, July 27 by Leerink Swann. On Friday, September 15 the stock rating was maintained by Jefferies with "Buy". The firm has "Outperform" rating by Robert W. Baird given on Wednesday, April 26. Blue Chip Partners Inc. boosted its position in Bristol-Myers Squibb by 0.8% during the 1st quarter. Macquarie accumulated 199,435 shares or 0.03% of the stock. BMY's profit will be $1.23B for 21.78 P/E if the $0.75 EPS becomes a reality. Manufacturers Life Insur The reported 19,279 shares stake. Therefore 47% are positive. Walker & Dunlop had 13 analyst reports since August 6, 2015 according to SRatingsIntel. UBS upgraded it to "Buy" rating and $75 target in Tuesday, September 29 report. The firm has "Sector Perform" rating given on Friday, August 14 by RBC Capital Markets. The company was upgraded on Thursday, October 1 by Argus Research. The rating was maintained by H.C. Wainwright with "Buy" on Wednesday, August 9. Keefe Bruyette & Woods has "Hold" rating and $4900 target. As per Tuesday, November 10, the company rating was downgraded by Morgan Stanley. The company was maintained on Wednesday, August 16 by Credit Suisse. The firm earned "Hold" rating on Wednesday, June 7 by Keefe Bruyette & Woods. The firm has "Hold" rating given on Monday, September 18 by Cowen & Co.

Investors sentiment decreased to 0.84 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It improved, as 15 investors sold Torchmark Corporation shares while 159 reduced holdings. 57 funds opened positions while 127 raised stakes. Panagora Asset Mngmt reported 2,301 shares stake. Acadian Asset Mgmt Ltd Liability Com accumulated 86,435 shares. Connor Clark & Lunn Investment Management Limited has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Point72 Asset Management LP reported 0.03% stake. Alliancebernstein L P owns 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 19,300 shares. Seaward Partnership invested in 0.22% or 79,810 shares. Highland Cap holds 2,587 shares or 0.03% of its portfolio. Channing holds 0.12% or 40,751 shares in its portfolio. Jones Financial Lllp has 6,537 shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.